Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
WARMINSTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the preliminary results of its tender offer (the “Offer”) to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”). The Offer proceeded […]
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
